Torben Plesner
YOU?
Author Swipe
View article: Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes Open
In the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diag…
View article: Sustained Improvement in Health‐Related Quality of Life in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: <scp>MAIA</scp> Final Analysis of Patient‐Reported Outcomes
Sustained Improvement in Health‐Related Quality of Life in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: <span>MAIA</span> Final Analysis of Patient‐Reported Outcomes Open
Objectives This final post hoc analysis evaluated patient‐reported outcomes from the Phase 3 MAIA study of daratumumab, lenalidomide, and dexamethasone (D‐Rd) versus lenalidomide and dexamethasone (Rd) after median 64.5‐month follow‐up in …
View article: The Prognostic Potential of <scp>circRNAs</scp> in Multiple Myeloma: Insights From Whole Bone Marrow and Purified Plasma Cells
The Prognostic Potential of <span>circRNAs</span> in Multiple Myeloma: Insights From Whole Bone Marrow and Purified Plasma Cells Open
Multiple myeloma (MM) is a haematological malignancy with abnormal proliferation of plasma cells in the bone marrow (BM), and MM patients with highly proliferative plasma cells have reduced overall survival. Circular RNAs (circRNAs) are en…
View article: Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma Open
The efficacy and favorable safety profile of daratumumab monotherapy in multiple myeloma (MM) was previously reported. Here, we present an updated pooled analysis of 148 patients treated with daratumumab 16 mg/kg. Data were combined from p…
View article: The role of trephine bone marrow biopsies in the era of measurable residual disease <b>—</b> Results from the CLL10 trial of the German CLL Study Group (GCLLSG)
The role of trephine bone marrow biopsies in the era of measurable residual disease <b>—</b> Results from the CLL10 trial of the German CLL Study Group (GCLLSG) Open
The advent of BCL-2 inhibitor-based time-limited therapies has currently replaced chemoimmunotherapy as one standard of care in chronic lymphocytic leukemia (CLL). Despite many differences in efficacy and safety profile, both treatment app…
View article: Low-Dose Venetoclax-Dexamethasone in t(11;14) Positive Relapsed and Refractory Multiple Myeloma; Interim Results from the Ongoing, Danish, Investigator-Initiated, Open Label, Phase 2 Victoria Study
Low-Dose Venetoclax-Dexamethasone in t(11;14) Positive Relapsed and Refractory Multiple Myeloma; Interim Results from the Ongoing, Danish, Investigator-Initiated, Open Label, Phase 2 Victoria Study Open
Background Venetoclax (VEN) is an oral BCL-2 inhibitor that is effective for the treatment of multiple myeloma (MM) with t(11;14), expressing high levels of BCL-2. In a previous phase 1 study, VEN was given to 66 patients [30 with t(11;14)…
View article: P816: PHARMACODYNAMIC ACTIVITY OF GEN3014 (HEXABODY-CD38) IN PATIENTS WITH MULTIPLE MYELOMA SUPPORTS ENHANCED COMPLEMENT DEPENDENT CYTOTOXICITY OF GEN3014 COMPARED TO DARATUMUMAB
P816: PHARMACODYNAMIC ACTIVITY OF GEN3014 (HEXABODY-CD38) IN PATIENTS WITH MULTIPLE MYELOMA SUPPORTS ENHANCED COMPLEMENT DEPENDENT CYTOTOXICITY OF GEN3014 COMPARED TO DARATUMUMAB Open
Topic: 13. Myeloma and other monoclonal gammopathies - Biology & Translational Research Background: CD38 monoclonal antibodies (mAb) have become part of backbone regimens for the treatment of multiple myeloma (MM). GEN3014 (HexaBody-CD38) …
View article: Proteomic profiling identifies apoptotic deregulation predictive of histological transformation in follicular lymphoma
Proteomic profiling identifies apoptotic deregulation predictive of histological transformation in follicular lymphoma Open
Introduction: Follicular lymphoma (FL) is a lymphoid neoplasia arising from germinal center B cells, characterized by the t(14;18) translocation and subsequent upregulation of anti-apoptotic B-cell lymphoma 2 (BCL2) proteins. While charact…
View article: P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY
P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY Open
Introduction: Daratumumab is a human IgGκ monoclonal antibody that is approved as monotherapy and in combination with standard-of-care regimens for relapsed/refractory multiple myeloma and in combination with standard-of-care regimens for …
View article: P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL
P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL Open
Introduction: In the primary analysis of the phase 3 MAIA trial (NCT02252172), daratumumab, lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) in transplant-ineligible (TIE) patients with newly diagnosed multipl…
View article: Plain Language Summary of the MAIA Study of Daratumumab Plus Lenalidomide and Dexamethasone for the Treatment of People with Newly Diagnosed Multiple Myeloma
Plain Language Summary of the MAIA Study of Daratumumab Plus Lenalidomide and Dexamethasone for the Treatment of People with Newly Diagnosed Multiple Myeloma Open
In the MAIA study, participants with multiple myeloma who took daratumumab plus lenalidomide and dexamethasone lived longer and had decreased myeloma protein levels than participants who took only lenalidomide and dexamethasone, indicating…
View article: Supplementary Figure 4 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Supplementary Figure 4 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Daratumumab is transferred from UM9 cells to monocytes.
View article: Supplementary Figure 3 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Supplementary Figure 3 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Daratumumab-mediated CD38 reduction on NK cells is abrogated by depleting monocytes from PBMCs.
View article: Data from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Data from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Purpose: Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma cells. The aim of this study was to investigate the clinical implications and the underlying mechanisms of daratumumab-mediated CD38 reduct…
View article: Supplemental Data from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Supplemental Data from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Supplemental Methods, Supplementary Tables, Supplementary Figure Legends
View article: Supplementary Figure 5 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Supplementary Figure 5 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Monocytes take up AF488-labeled daratumumab-CD38 complexes from PKH-26-stained UM9 cells.
View article: Supplemental Data from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Supplemental Data from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Supplemental Methods, Supplementary Tables, Supplementary Figure Legends
View article: Supplementary Figure 5 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Supplementary Figure 5 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Monocytes take up AF488-labeled daratumumab-CD38 complexes from PKH-26-stained UM9 cells.
View article: Supplementary Figure 2 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Supplementary Figure 2 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Daratumumab-mediated CD38 reduction of MM cells in the presence of PBMCs as shown by Western blot analysis.
View article: Supplementary Figure 2 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Supplementary Figure 2 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Daratumumab-mediated CD38 reduction of MM cells in the presence of PBMCs as shown by Western blot analysis.
View article: Supplementary Figure 6 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Supplementary Figure 6 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Transfer of surface membrane from UM9 cells to monocytes.
View article: Supplementary Figure 1 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Supplementary Figure 1 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Loss of CD38 from the MM cell membrane is associated with reduced CDC and ADCC
View article: Data from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Data from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Purpose: Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma cells. The aim of this study was to investigate the clinical implications and the underlying mechanisms of daratumumab-mediated CD38 reduct…
View article: Supplementary Figure 6 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Supplementary Figure 6 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Transfer of surface membrane from UM9 cells to monocytes.
View article: Supplementary Figure 3 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Supplementary Figure 3 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Daratumumab-mediated CD38 reduction on NK cells is abrogated by depleting monocytes from PBMCs.
View article: Supplementary Figure 1 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Supplementary Figure 1 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Loss of CD38 from the MM cell membrane is associated with reduced CDC and ADCC
View article: Supplementary Figure 4 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Supplementary Figure 4 from Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab Open
Daratumumab is transferred from UM9 cells to monocytes.
View article: Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma Open
Introduction This phase 1 trial assessed the safety, pharmacokinetics, and preliminary antitumor activity of RO7297089, an anti-BCMA/CD16a bispecific antibody. Methods RO7297089 was administered weekly by intravenous infusion to patients w…
View article: Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial Open
PURPOSE With the initial analysis of POLLUX at a median follow-up of 13.5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone…